| 名稱 | CD47/PD-L1 Dual Target Cell |
| 型號 | CBP74155 |
| 報價 |  |
| 特點 | CD47/PD-L1 Dual Target Cell |
產品搜索
相關文章
聯系我們
聯系人：蔣經理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區緯地路9號
Email： zhangxiangwen@cobioer.com
產品展示 / PRODUCTS
- 詳細內容
| CBP74155 | |
| I. Background | |
CD47 (also known as Rh-associated protein, GP42, integrin-associated protein (IAP), and neurophilin,) is an immunoglobulin-like protein that interacts with its receptor, Signal-regulatory protein alpha (SIRPα), on macrophages. This binding interaction regulates transmigration, oxidative burst cytokine production, and phagocytosis, creating a “don’t eat me" signal. CD47 is ubiquitously expressed on the surface of normal cells, but is overexpressed in numerous cancer cells, where it is thought to contribute to the resistance of tumors to phagocyte-dependent clearance. The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and enables cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes | |
| II. Introduction | |
| Expressed gene: | CD47、PD-L1 |
| Stability: | 32 passages(in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | Rh-associated protein, GP42, integrin-associated protein (IAP), and neurophilin, Programmed Cell Death 1 Ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, CD274, PDCD1L1 |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+ 200ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose response of Blocking Antibodies in SIRPα/PD-1 Dual Effector Reporter Cells(C18) With CD47/PD-L1 Dual Target Cells. | |
